CS Paper Radar

DrugReason: Dynamic Multi-View Reasoning over Knowledge Graph and Language Evidence for Drug Repurposing

Zijie Liu, Hongxuan Li, Zhen Tan, Jinhao Duan, Baixiang Huang, Zunpeng Liu, Kai Shu, Tianlong Chen

cs.LG cs.AI ·submitted 2026-09-06 18:54 UTC · v2
top venuecode/data

Abstract

Drug repurposing aims to identify new therapeutic uses for existing compounds and, compared with de novo drug discovery, offers a faster and more cost-effective path to clinical translation. However, the space of candidate drug-disease pairs is enormous and their underlying relationships often depend on complex multi-hop biological mechanisms, making it difficult to reliably predict which pairs represent true therapeutic relationships. Existing approaches tackle this from two directions: knowledge graph-based methods organize curated biomedical evidence into structured relational networks for grounded multi-hop reasoning, while LLM-based methods leverage pretrained knowledge to generate flexible mechanistic rationales. Yet neither is sufficient alone - KGs are confined to observed graph structure while LLMs lack factual grounding and risk hallucination. To address this gap, we propose DrugReason, a multi-view reasoning framework that integrates grounded KG reasoning with LLM-generated mechanistic inference for drug repurposing. DrugReason adaptively routes diverse reasoning paths to specialized experts conditioned on the query context, while a cross-expert distillation objective enables knowledge sharing without sacrificing expert specialization. Experiments on PharmaDB, DDInter, and DrugBank show that DrugReason improves average performance over strong single-view reasoning baselines and achieves competitive or superior results compared with graph-based alternatives, while providing interpretable routing-based predictions.

Comment
EMNLP 2026 Main Conference Code: https://github.com/jesseliu0913/DrugReason

Closest papers

Nearest neighbours by meaning across the whole index.

Benchmarking Large Language Models on Heterogeneous Cognitive and Biomedical Knowledge Graphs: The Role of Graph Grounding in Multi-Hop Reasoning and Hallucination Mitigation

cs.AI cs.CLcs.LG ·2026-11-05 ·Ali Sarabadani, Kheirolah Rahsepar Fard, Tahereh Jeirani
benchmarkdataset similarity 0.72
Abstract

Large language models (LLMs) are increasingly used in biomedical and cognitive neuroscience, but their ability to reason reliably over heterogeneous knowledge graphs (KGs) remains unclear. We benchmark five LLMs (GPT-5.1, Gemini 2.0 Pro, Llama 3, Qwen, and BioGPT) across five KGs: DrugBank, NeuroSynth, Cognitive Atlas, Brain Map, and GDPKG. We introduce a multitier query dataset to evaluate reasoning depth and factual accuracy under KG-aware (graph-grounded) and KG-agnostic conditions. Inter-annotator agreement was substantial, with Cohen's kappa of 0.781 (range: 0.753-0.807) and Fleiss' kappa of 0.77. Results show that general-purpose models, particularly GPT-5.1 and Gemini 2.0 Pro, generally outperform domain-specific models on multi-hop and high-level reasoning tasks, although performance declines as query complexity increases. KG grounding reduces hallucination rates across all evaluated models. Contrary to our initial hypothesis, domain-specific models do not consistently outperform general-purpose models on specialized tasks without graph grounding. These findings highlight the value of combining broad language-model capabilities with structured domain knowledge. We provide practical guidance for selecting LLM-KG integration strategies based on task complexity and computational constraints, and discuss hybrid neurosymbolic architectures for personalized medicine, cognitive disorder diagnosis, and explainable AI.

0.07

Aligning Multimodal Patient Evidence with Biomedical Knowledge Graphs for Clinical LLMs

cs.LG cs.CL ·2026-10-05 ·Jiawen Du, Arshan Ali Khan, Chenhao Zhang, Zachary Plotkin, Li Shen +5 more
similarity 0.71
Abstract

Clinical questions often depend on linking a patient's multimodal evidence to external biomedical knowledge, yet existing predictive systems rarely represent such links explicitly, so they can neither be traced to their evidence sources nor removed to measure their contributions. We present MM-KG (Multimodal Knowledge Graph), which represents heterogeneous, multimodal patient observations and biomedical concepts as separate layers in one typed graph, joined by explicit alignment edges. First, modality-specific harmonizers convert EHR text, imaging, genomic, and biospecimen data into typed observations mapped to UMLS concepts, which a route-prioritized aligner links to a biomedical knowledge graph. Query-conditioned retrieval then selects a compact subgraph for downstream use by a large language model or a graph neural network. We build MM-KGs for MIMIC-IV and ADNI, and evaluate them with a 2x2 design that separates patient evidence, biomedical knowledge, and their interaction. On questions that require both sources, neither source alone performs far above chance, whereas their combination yields a drug-controlled AUROC interaction of +0.194 on MIMIC and +0.299 on ADNI. On held-out five-candidate ranking, MM-KG outperforms MindMap by +0.131 Hits@1 and leads an adapted GraphCare on the items that require consulting the patient, and deleting the single answer-bearing relation from the retrieved packet returns Hits@1 to the no-knowledge baseline. Finally, query-conditioned retrieval reaches 0.731 AUROC with 6.8x less context than the strongest generic policy, whereas static knowledge graph context gives no consistent gain on ordinary outcome prediction. Knowledge graphs thus benefit clinical LLMs not as background context but as explicit links between multimodal patient evidence and the relation a question requires, and MM-KG makes these links retrievable, traceable, and testable.

0.06

AdaPath: Query-Adaptive Path-Finding via Path-Bank for Multi-Hop Implicit Biomedical KGQA

cs.AI ·2026-08-31 ·Jun Hyeong Kim, Dongki Kim, Yinhua Piao, Sung Ju Hwang
top venuebenchmarkcode/data similarity 0.69
Abstract · 25 pages, 6 figures, 30 tables

Path-finding over knowledge graphs has become an effective way to ground LLM reasoning on multi-hop questions. However, biomedical QA introduces two distinct challenges that general-domain methods are not designed for: (i) queries do not expose intermediate reasoning and can be answered through multiple valid pathways, and (ii) biomedical knowledge graphs are densely connected, so path-finding methods easily take wrong turns. To address these challenges, we propose AdaPath, a path-finding framework that retrieves query-adaptive meta-paths from Path-Bank, which captures both query semantics and biomedical knowledge graph structure. AdaPath provides the missing cues in biomedical queries while effectively pruning dense knowledge graph neighborhoods during multi-hop reasoning. We further release BioStrat-QA, a biomedical KGQA benchmark that stratifies multi-hop queries by how much intermediate reasoning they expose. Across biomedical KGQA benchmarks, AdaPath consistently outperforms baselines, sustaining meaningful path-finding even when multi-hop queries expose less surface information. The source code is available at https://github.com/Jun-Hyeong-Kim/AdaPath.

0.55

RES-MR: Risk-Aware Reasoning for Explainable and Safe Medication Recommendation

cs.LG cs.AIcs.IR ·2026-10-10 ·Cong Wang, Jin Li, Shoujin Wang, Yishuo Li, Huilin Gu +1 more
top venuebenchmarkcode/datahighly cited similarity 0.69
Abstract · 12 pages

Medication recommendations seek to deliver personalized drug combinations based on patients' clinical information, where ensuring transparent decision-making and personalized safety are of paramount importance. However, existing approaches predominantly operate as ``black boxes'', offering limited interpretability and hindering clinician trust. Furthermore, they typically rely on fixed, patient-agnostic safety constraints, neglecting the heterogeneity of risk tolerance across individuals, which poses significant risks to vulnerable populations. To address these gaps, we propose \textbf{RES-MR}, a novel Risk-aware Reasoning framework for Explainable and Safe Medication Recommendation using LLMs. RES-MR follows a two-stage training paradigm: (1) an explainable clinical reasoning distillation stage to elicit diagnostic capabilities by fine-tuning on synthesized reasoning trajectories, grounded in patient-specific knowledge from graph retrieval; and (2) a risk-aware policy optimization stage to dynamically balance therapeutic efficacy with personalized safety. This stage employs disentangled drug factors to construct patient-specific reference prototypes that capture desired therapeutic drug features and risk features to avoid. These prototypes enable risk boundary calibration and guide the model toward safe recommendations via reward shaping and clipping. Extensive experiments on benchmark datasets demonstrate that RES-MR significantly outperforms state-of-the-art baselines in terms of accuracy, safety, and explainability. Our code and data are available at: https://github.com/wangcong2001/RES-MR.

0.78

MT-RGCN-DTI: A Multi-Task Relational Graph Convolutional Network for Drug-Target Interaction Prediction

cs.LG cs.AI ·2026-11-15 ·Dheeran Sankaran, R Yadunandan, Daniele Santoni, Nimisha Ghosh
benchmarkcode/data similarity 0.69
Abstract

Prediction of drug-target interaction (DTI) has become a very crucial part of drug discovery. With the increase in the data volume, it has become very important to improve prediction accuracy by integrating multiple data sources. In this regard, utilising multiple resources in the form of heterogeneous information network to address DTI prediction can be rewarding. In this work, we propose a heterogeneous information network based multi-task DTI prediction model which leverages the advantages of relation graph convolutional network (RGCN). To achieve this, the model employs drug-target interaction network, drug-drug similarity network and protein-protein similarity network to construct a heterogeneous information network. Moreover, we use a knowledge graph embedding scoring functions to model interactions between drug and targets, specifically DistMult and ComplEx as decoders over the learned node representations. We performed extensive experiments on multiple benchmark datasets and compared with state-of-the-art methods. We observed that the proposed model shows competitive performance, thereby confirming the effectiveness of our approach. The codes and datasets are available at https://github.com/Dheeran-S/MT-RGCN-DTI/.

0.19

BiGSyn: A Bi-Level Heterogeneous Graph Contrastive Learning Framework for Interpretable Drug Synergy Prediction

cs.AI ·2026-11-16 ·Senquan Wang, Hui Fang, Haoran Nan, Xingwei Wang, Qiang He
publishedbenchmark similarity 0.68
Abstract · 2026 IEEE International Conference on Data Mining (ICDM 2026)

Drug combination therapy has become a mainstream of modern medicine, with the potential to enhance efficacy, reduce toxicity, and overcome drug resistance. However, identifying synergistic drug combinations remains challenging, as it requires modeling complex interactions across multiple biological scales---from atom-level molecular structures to entity-level relations in biological networks. Existing approaches typically model these levels in isolation, overlooking complementary signals and long-range dependencies. To address these limitations, we propose BiGSyn, a Bi-level heterogeneous Graph contrastive learning framework for drug Synergy prediction. Specifically, BiGSyn leverages heterogeneous graph transformers to extract high-order dependencies from molecular graphs and biological networks, and introduces a bi-level contrastive learning objective to bridge the cross-level semantic gap. Extensive experiments on two benchmark datasets show that BiGSyn consistently outperforms state-of-the-art baselines. Moreover, its attention mechanism highlights key molecular substructures and biological interactions driving synergy, providing interpretable insights.

0.18

Enhancing Multi-Step Chemical Mechanism Prediction with Graph-Guided Preference Data

cs.AI ·2026-11-09 ·Yu Zhang, Ruijie Yu, Xuelin Zhao, Jinming Yang, Feng Zhu +3 more
similarity 0.68
Abstract · 5 figures, 3tables

Predicting multi-step chemical reaction mechanisms requires identifying plausible intermediates and correctly ordering the elementary reaction steps. Existing computational methods focus on single-step elementary reaction prediction, limiting their ability to generalize to unseen reaction spaces. We introduce a graph-guided framework for multi-step chemical mechanism prediction that leverages a chemical mechanism knowledge graph (ChemMechKG) to guide large language models (LLMs). To improve pathway prediction, we develop a graph-aligned reaction mechanism predictor (GRMP) that uses graph neural networks to generate synthetic candidate pathways for pathway optimization. During inference, we design a relation retrieval (RR) module to extract relevant graph evidence from the KG for pathway refinement. Experiments show that GRMP achieves the highest pathway accuracy among all compared methods on ChemMechQA and oMe-Gold, reaching 48.1% and 57.9%, respectively. On a fixed sample of 110 out-of-distribution reactions from ChemMechQA-Hard, GRMP achieves 36.4% top-1 pathway accuracy. LLM-as-Judge and human assessment further demonstrate its ability to generalize to unseen reactions.

0.19

CircuitATLAS: Agentic reasoning over a systems neuroscience knowledge graph for target discovery in circuitopathies

cs.AI q-bio.QMq-bio.NC ·2026-10-07 ·Gabriel Ocana-Santero, Marko Tvrdic
similarity 0.68
Abstract · 22 pages, 5 figures, 4 tables

Drug discovery for neurological disease has traditionally centered on the molecules altered by disease. But the molecules that cause pathology are not necessarily the best points from which to reverse it. Here, we ask which otherwise unaltered molecular control points can be engaged to restore pathological neural circuits toward functional states. We present CircuitATLAS, a provenance-grounded systems-neuroscience knowledge graph and agentic framework for target discovery in circuitopathies. It structures literature-derived relationships across diseases, phenotypes, electrophysiology, circuits, brain regions, cell types and molecular effectors, while deliberately excluding direct disease-gene and disease-protein edges to reduce shortcut reasoning. The graph contains 3.83 million nodes and 7.66 million edges, including 5.31 million LLM-extracted relations, and incorporates structured datasets such as the Human Cell Atlas and new multimodal in vivo measurements. We then introduce an agentic workflow that reasons from measurable disease phenotypes through their circuit and cellular substrates to molecular interventions, therapeutic feasibility and clinical constraints. Finally, we introduce a human-governed in vivo lab-in-the-loop linking hypothesis generation to experimental iteration. Within this framework an agent nominated ATP1A3, the neuronal alpha3 Na+/K+-ATPase, as a control point on cortical excitability; interneuron-restricted expression of ATP1A3 abolished the beta- and gamma-band response to a focal 4-aminopyridine challenge in vivo, and the validated target was then carried into a structure-guided small-molecule campaign terminating in a defined assay to resolve the direction of modulation. CircuitATLAS thus provides a framework for discovering therapeutics based not only on what is molecularly disrupted in disease, but on what can be controlled to restore circuit function.

0.34